Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Kidney Cancer: early-phase trial registry
19 of 69 indexed Kidney Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #201 of 28,707 conditions by registered trial count.
69 US clinical trials · 19 currently recruiting · #201 of 28,707 conditions by registered trial count
Kidney Cancer: 69 US clinical trials tracked, 19 recruiting.
Kidney Cancer is the subject of 69 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition kidney-cancer
OPEN 19 | RECR 28% | LATE 4 | EARLY 42 | RANK #201 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Hypoxia (28% recruiting · 40 trials)
Kidney Cancer lists 19 open slots (28% of 69 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Kidney Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Kidney Cancer is recruiting below its size-band peers.
19 of 69 indexed trials (27.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Kidney Cancer trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 6 of 69 trials (8.7%). 51 distinct sponsors appear on at least one study for this condition label.
-
Typical Kidney Cancer enrolment sits around 60 participants.
Median target enrolment is 60 among the 61 trials that report a genuine target (sentinel values excluded). 35 of those (57.4%) plan for fewer than 100 participants.
-
Kidney Cancer research is mostly interventional.
60 interventional and 9 observational studies make up this index (87% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
69 total, page 2 of 2
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT02964078
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Jorge A. Garcia, MD
NCT00853021
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Weill Medical College of Cornell University
NCT00003656
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
OHSU Knight Cancer Institute
NCT00331409
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00024258
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Stanford University
NCT04508725
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
NCT00085436
Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
Duke University
NCT00005816
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
NCT00276835
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
The Cleveland Clinic
NCT00401128
Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer
Case Comprehensive Cancer Center
NCT00278174
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
NCT00003308
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Case Comprehensive Cancer Center
NCT00006864
Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
Eastern Cooperative Oncology Group
NCT00005045
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
Baylor College of Medicine
NCT00073879
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT00020540
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
SWOG Cancer Research Network
NCT00016939
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University School of Medicine
NCT00003107
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
City of Hope Medical Center
NCT00006384
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 28 |
| Phase 3 | 2 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Kidney Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Kidney Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Kidney Cancer page
69 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Kidney Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Kidney Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kidney Cancer condition card totals 69 registered trials; most-linked intervention recombinant interferon alfa; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.